RxDoctor Payments Data

Anthony Nebor, MD

Internal Medicine · Allen, TXNPI 1154685881

Payments from drug & device makers

$14,707in general payments, 2019–2025

Across 254 payments — averaging $57.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • GSK$1K
  • Medical Device Business Services, Inc.$1K
  • Amgen$768
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$4,07228%
  • Food & beverage$6,02941%
  • Education$4,60631%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,707 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$899,793
Medicare patients
374
Services billed
28,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$155,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter148$130,861
Stiolto RespimatTiotropium Br/Olodaterol Hcl179$101,385
Spiriva RespimatTiotropium Bromide119$76,942
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$63,814
Breo ElliptaFluticasone/Vilanterol62$26,462
Arnuity ElliptaFluticasone Furoate52$10,262
Combivent RespimatIpratropium/Albuterol Sulfate12$6,913
Albuterol Sulfate HfaAlbuterol Sulfate322$6,749
Advair HfaFluticasone Propion/Salmeterol16$6,365
SymbicortBudesonide/Formoterol Fumarate20$5,489
Epinephrine19$3,519
Varenicline Tartrate13$2,642
Azelastine Hcl53$1,340
Fluticasone Propionate42$1,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$93$340,354322 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,352$167,586262 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,377$69,30389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →